FDA Considers Making Narcan Opioid Overdose Antidote Available Without Prescription

Two hands cradling a nasal spray dispenser for naloxone.
February 15, 2023
Clinical Associate Professor in the Division of Pharmacotherapy Dr. Kirk Evoy spoke to CNN about the possibilities of making naloxone, a medication used to reverse or reduce the effects of opioids, available over-the-counter.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

Reveles and Evoy Earn Promotions

A woman and a man smiling.
February 25, 2022
Two of the college's distinguished faculty in the Division of Pharmacotherapy were recommended for promotion by President Hartzell. Dr. Kelly R. Reveles will assume the rank of associate professor and Dr. Kirk Evoy will become a clinical associate professor. Both promotions go into effect September 1, 2022.

Immunologic Resilience: A New Metric to Accurately Gauge COVID-19’s Path

The COVID-19 virus.
September 8, 2021
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.

Laura Cannon: An Empathetic Voice for Patients & Students

A woman smiling.
January 5, 2021
Laura Cannon, Pharm.D., MPH, is an oncology pharmacist and clinical assistant professor at the UT College of Pharmacy. She was in her residency when her late husband was diagnosed with cancer. Her experience shapes her unique perspective as she works to simplify the education process surrounding cancer treatment.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.